Single-Cell Transcriptomic Identification of Novel MMP and TLR4 Inhibitors for Rheumatoid Arthritis via Synovial Bioactivity Profiling

Read full text Summarise with VIRAT
Authors: Glen Charles Ritschel, Claude
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Companion research paper to provisional patent application disclosing computational drug repurposing candidates for rheumatoid arthritis. Single-cell RNA sequencing data from RA synovial tissue (GSE200815, n=9 donors) and osteoarthritis control (GSE152805, n=9 donors) were analyzed using scVI variational autoencoder dimensionality reduction, Leiden clustering, and Wilcoxon differential expression. 11,722 significant differentially expressed genes were identified across 10 inflammatory synovial cell populations (90,781 cells). Top DE genes included PRG4, CD74, HLA-DRA, APOE, and IFI27, reflecting FLS activation, antigen presentation, and interferon signaling. ChEMBL multi-target bioactivity screening yielded 842 patent-novel NOVEL_ALL candidates. Three independent MMP1/MMP2/MMP3 inhibitors ranked at the top, mechanistically coherent with PRG4 upregulation as the dominant FLS signal. Five TLR4 inhibitors were identified as a secondary therapeutic axis. Authors: Glen Charles Ritschel (Ritschel Research, Tega Cay SC) and Claude (Anthropic, San Francisco CA).

Fields of Study & Subjects

Rheumatoid Arthritis Research and Therapies Computational Drug Discovery Methods Natural Compounds in Disease Treatment

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
30 March 2026
Language
EN
Document type
Preprint